Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4585323
Max Phase: Preclinical
Molecular Formula: C92H133N13O28S
Molecular Weight: 1901.21
Molecule Type: Unknown
Associated Items:
ID: ALA4585323
Max Phase: Preclinical
Molecular Formula: C92H133N13O28S
Molecular Weight: 1901.21
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)N(C)[C@H](CC(=O)O)C(=O)N(C)[C@@H](Cc1cccc2ccccc12)C(N)=O
Standard InChI: InChI=1S/C92H133N13O28S/c1-6-7-32-69(90(122)105(5)76(55-84(115)116)91(123)104(4)75(85(93)117)53-63-29-26-28-62-27-22-23-30-66(62)63)101-88(120)73(52-64-56-96-68-33-25-24-31-67(64)68)99-79(108)57-97-86(118)71(50-60(2)3)102-87(119)72(51-61-36-38-65(39-37-61)133-134(126,127)128)103-89(121)74(54-83(113)114)100-81(110)59-132-49-47-130-45-43-95-80(109)58-131-48-46-129-44-42-94-77(106)41-40-70(92(124)125)98-78(107)34-20-18-16-14-12-10-8-9-11-13-15-17-19-21-35-82(111)112/h22-31,33,36-39,56,60,69-76,96H,6-21,32,34-35,40-55,57-59H2,1-5H3,(H2,93,117)(H,94,106)(H,95,109)(H,97,118)(H,98,107)(H,99,108)(H,100,110)(H,101,120)(H,102,119)(H,103,121)(H,111,112)(H,113,114)(H,115,116)(H,124,125)(H,126,127,128)/t69-,70-,71-,72-,73-,74-,75-,76+/m0/s1
Standard InChI Key: BMZYXLWLLWZVBA-PPAHWLEZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1901.21 | Molecular Weight (Monoisotopic): 1899.9104 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Sensfuss U, Kruse T, Skyggebjerg RB, Uldam HK, Vestergaard B, Huus K, Vinther TN, Reinau ME, Schéele S, Clausen TR.. (2019) Structure-Activity Relationships and Characterization of Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor Agonists., 62 (3): [PMID:30624060] [10.1021/acs.jmedchem.8b01558] |
Source(1):